XML 64 R54.htm IDEA: XBRL DOCUMENT v3.22.1
Geneos Therapeutics, Inc. - Preferred stock Investment (Details) - USD ($)
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Noncontrolling Interest [Line Items]    
Share in current and accumulated net loss of Geneos for the three months ended March 31, 2022 $ (2,165,213) $ (434,387)
Series A-2 One Preferred Stock    
Noncontrolling Interest [Line Items]    
Beginning balance 1,999,998  
Remeasurement of Geneos Series A-1 preferred stock 165,215  
Share in current and accumulated net loss of Geneos for the three months ended March 31, 2022 (2,165,213)  
Ending balance $ 0